1 Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences, University of Calgary, Calgary, Alberta.
2 Department of Family Medicine, University of Calgary, Alberta.
Can J Psychiatry. 2017 Sep;62(9):673-683. doi: 10.1177/0706743717719898. Epub 2017 Jul 18.
While antipsychotic medications are the mainstay of therapy for individuals with schizophrenia and psychotic disorders, their use is associated with adverse effects on physical health that require the attention and care of prescribers.
We used the ADAPTE process to adapt existing guideline recommendations from the National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) guidelines on the dosing of antipsychotics and antipsychotic polypharmacy, screening for adverse effects of antipsychotics, and management of metabolic and extrapyramidal side effects to the Canadian context.
Prescribers are encouraged to use the lowest effective dose and to avoid the routine use of multiple antipsychotics. Scheduled monitoring of body mass index, waist circumference, blood pressure, glucose, lipids, prolactin, electrocardiograms, and extrapyramidal symptoms is recommended. Lifestyle interventions are recommended to mitigate antipsychotic-induced weight gain. Prescribers should follow Canadian guidelines on the treatment of obesity, dyslipidemia, and diabetes. Recommendations on antipsychotic drug choice are made for users particularly concerned about extrapyramidal symptoms.
Careful monitoring and attention by prescribers may mitigate adverse effects associated with antipsychotic medications.
虽然抗精神病药物是治疗精神分裂症和精神病患者的主要方法,但它们的使用会对身体健康产生不良反应,需要医生关注和护理。
我们使用 ADAPTE 流程,将英国国家卫生与临床优化研究所(NICE)和苏格兰校际指南网(SIGN)关于抗精神病药物剂量、抗精神病药物联合用药、抗精神病药物不良反应筛查以及代谢和锥体外系副作用管理的指南建议进行改编,以适应加拿大的情况。
鼓励医生使用最低有效剂量,避免常规使用多种抗精神病药物。建议定期监测体重指数、腰围、血压、血糖、血脂、催乳素、心电图和锥体外系症状。建议采取生活方式干预来减轻抗精神病药物引起的体重增加。医生应遵循加拿大关于肥胖、血脂异常和糖尿病的治疗指南。对于特别关注锥体外系症状的使用者,还提出了关于抗精神病药物选择的建议。
医生的仔细监测和关注可能会减轻抗精神病药物相关的不良反应。